Latest market price
41.85
-3.21-7.12%
Earnings
Down 7.1% — Reported earnings — EPS in line, revenue beat by 2%.
High confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | 30.55 | EPS (ttm) | 1.37 | Insider Own | 17.50% | Shs Outstand | 89.51M | Perf Week | -4.32% |
| Market Cap | 3.75B | Forward P/E | 19.14 | EPS next Y | 2.19 | Insider Trans | -19.23% | Shs Float | 65.22M | Perf Month | 46.12% |
| Enterprise Value | 3.59B | PEG | 1.63 | EPS next Q | — | Short Float | 26.53% | Perf Quarter | -52.65% | ||
| Income | 139.00M | P/S | 8.31 | EPS this Y | — | Short Ratio | 5.62 | Perf Half Y | 8.76% | ||
| Sales | 451.00M | P/B | 19.21 | EPS next Y | 7.86% | ROA | 26.56% | Short Interest | 17.30M | Perf YTD | 21.34% |
| Book/sh | 2.18 | P/C | 13.19 | EPS next 5Y | 18.74% | ROE | 149.64% | 52W High | 93.61 -55.29% | Perf Year | 80.39% |
| Cash/sh | 3.17 | P/FCF | 62.43 | EPS past 3/5Y | — | ROIC | 46.86% | 52W Low | 22.21 88.43% | Perf 3Y | 563.23% |
| Dividend Est. | — | EV/EBITDA | 20.17 | Sales past 3/5Y | 114.54% 175.25% | Gross Margin | 92.48% | Volatility | 6.11% 8.58% | Perf 5Y | 1065.74% |
| Dividend TTM | — | EV/Sales | 7.96 | EPS Y/Y TTM | — | Oper. Margin | 37.39% | ATR (14) | 3.80 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 2.12 | Sales Y/Y TTM | 2273.68% | Profit Margin | 30.74% | RSI (14) | 46.73 | Recom | 2.44 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.31 | EPS Q/Q | 251.02% | SMA20 | 15.60% | Beta | 0.43 | Target Price | 72.36 |
| Payout | 0.00% | Debt/Eq | 0.66 | Sales Q/Q | 1811.11% | SMA50 | -20.22% | Rel Volume | 0.75 | Prev Close | 45.06 |
| Employees | 216 | LT Debt/Eq | 0.66 | Earnings | Nov 02 | SMA200 | -22.95% | Avg Volume | 3.44M | Price | 41.85 |
| IPO Date | Jul 26, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -0.37% 1.90% | Net Debt/EBITDA | -0.88 | Volume | 2,582,625 | Change | -7.12% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-15-26 | Reiterated | RBC Capital | $130 → $65 | |
| Oct-15-26 | Reiterated | HC Wainwright & Co. | Buy | $58 → $65 |
| Oct-14-26 | Upgrade | LifeSci Capital | Market Perform → Outperform | |
| Oct-14-26 | Upgrade | BTIG | Neutral → Buy | $109 → $70 |
| Oct-14-26 | Reiterated | Needham | Buy | $19 → $58 |
| Oct-14-26 | Reiterated | Wells Fargo | Equal Weight | $30 → $33 |
| Oct-02-26 | Reiterated | Wedbush | Underperform | $3.00 → $58 |
| Oct-02-26 | Downgrade | Wells Fargo | Overweight → Equal Weight | $108 → $30 |
| Oct-02-26 | Reiterated | HC Wainwright & Co. | Buy | $36 → $58 |
| Oct-01-26 | Downgrade | Raymond James | Strong Buy → Outperform | $106 → $53 |
Latest News· Times ET
Oct-29-26
Oct-28-26
Oct-26-26
Oct-22-26
Oct-22-2611:35AM
Oct-21-26
Oct-21-2610:00AM
Oct-16-26
Oct-16-2605:26AM
Oct-14-26
01:16PM
Liquidia shares surge 25% as settlement ends United Therapeutics litigationproactiveinvestors.com
11:05AM
10:02AM
08:57AM
Oct-13-26
Oct-13-2605:44PM
Oct-12-26
Oct-12-2602:55PM
11:02AM
Liquidia (NASDAQ:LQDA) Shares Gap Up – Here’s Whydefenseworld.net
Company
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 451 | 158 | 14 | 17 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 34 | 13 | 6 | 3 | — | — | — | — | — | |
| Gross Profit | 417 | 145 | 8 | 15 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 192 | 157 | 82 | 45 | — | — | — | — | — | |
| Research and Development | 55 | 39 | 48 | 43 | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | -1 | 0 | — | — | — | — | — | |
| Operating Income | 170 | -51 | -121 | -73 | — | — | — | — | — | |
| Interest Expense | 26 | 24 | 12 | 6 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 7 | 3 | 1 | — | — | — | — | — | |
| Net Income Before Taxes | 150 | -69 | -130 | -79 | — | — | — | — | — | |
| Income Taxes | 11 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | 139 | -69 | -130 | -79 | — | — | — | — | — | |
| Net Income From Continuing Operations | 139 | -69 | -130 | -79 | — | — | — | — | — | |
| Net Income | 139 | -69 | -130 | -79 | — | — | — | — | — | |
| EPS (Recurring) | 1.57 | -0.80 | -1.66 | -1.21 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.57 | -0.80 | -1.66 | -1.21 | — | — | — | — | — | |
| EPS (Diluted) | 1.37 | -0.80 | -1.66 | -1.21 | — | — | — | — | — | |
| EBITDA | 178 | -43 | -116 | -70 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 30.55 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 8.26 | 18.77 | 66.36 | 46.00 | — | — | — | — | — | |
| Gross Margin | 92.46 | 91.77 | 57.14 | 88.24 | — | — | — | — | — | |
| Operating Margin | 37.69 | -32.28 | -864.29 | -429.41 | — | — | — | — | — | |
| Net Margin | 30.82 | -43.67 | -928.57 | -464.71 | — | — | — | — | — | |
| Shares Outstanding | 89 | 86 | 79 | 65 | — | — | — | — | — | |
| Market Capitalization | 3,725 | 2,966 | 929 | 782 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Adair Jason | Chief Business Officer | Oct 26 '26 | Sale | 43.19 | 688 | 29,715 | 177,269 | Oct 28 |
| Boyle Dana | Chief Accounting Officer | Oct 26 '26 | Sale | 43.19 | 1,581 | 68,283 | 164,028 | Oct 28 |
| Schundler Russell | General Counsel | Oct 12 '26 | Sale | 28.48 | 13,692 | 389,948 | 602,841 | Oct 13 |
| JEFFS ROGER | Chief Executive Officer | Oct 12 '26 | Sale | 28.48 | 32,744 | 932,549 | 1,125,848 | Oct 13 |
| Khindri Sanjeev | Chief Development Officer | Oct 12 '26 | Sale | 28.48 | 1,101 | 31,356 | 64,846 | Oct 13 |
| Boyle Dana | Chief Accounting Officer | Oct 12 '26 | Sale | 28.48 | 5,892 | 167,804 | 165,609 | Oct 13 |
| Moomaw Scott | Chief Commercial Officer | Oct 12 '26 | Sale | 28.48 | 8,863 | 252,418 | 181,487 | Oct 13 |
| Saggar Rajeev | Chief Medical Officer | Oct 12 '26 | Sale | 28.48 | 9,218 | 262,529 | 126,368 | Oct 13 |
| Kaseta Michael | CFO and COO | Oct 12 '26 | Sale | 28.48 | 18,938 | 539,354 | 340,148 | Oct 13 |
| Adair Jason | Chief Business Officer | Oct 12 '26 | Sale | 28.48 | 7,301 | 207,932 | 177,957 | Oct 13 |
| Krepp Sarah | Chief Human Resource Officer | Oct 12 '26 | Sale | 28.48 | 5,245 | 149,378 | 115,241 | Oct 13 |
| Boyle Dana | Chief Accounting Officer | Oct 09 '26 | Option Exercise | 0.00 | 3,178 | 0 | 171,501 | Oct 13 |
| Adair Jason | Chief Business Officer | Oct 09 '26 | Option Exercise | 0.00 | 10,248 | 0 | 185,258 | Oct 13 |
| Schundler Russell | General Counsel | Oct 09 '26 | Option Exercise | 0.00 | 10,167 | 0 | 616,533 | Oct 13 |
| Moomaw Scott | Chief Commercial Officer | Oct 09 '26 | Option Exercise | 0.00 | 7,466 | 0 | 190,350 | Oct 13 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.